Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

Cellosaurus HL-60 (CVCL_0002)

[Text version]
Cell line name HL-60
Synonyms HL 60; HL.60; HL60; Human Leukemia-60
Accession CVCL_0002
Resource Identification Initiative To cite this cell line use: HL-60 (RRID:CVCL_0002)
Comments Group: Space-flown cell line (cellonaut).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2392-I.
Population: Caucasian.
Biotechnology: Used a source of mitochondrial DNA for USA forensic testing.
Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257).
Doubling time: 16 hours (PubMed=8343448); 28 hours (PubMed=25984343); ~40 hours (DSMZ=ACC-3).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; PubMed=12661003; Sanger).
Omics: Array-based CGH.
Omics: Cell surface proteome.
Omics: CTCF ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Mitochondrial genome sequenced.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Anecdotal: Established at the 60th attempt to culture human leukemia biopsies in Gallo's lab. All the preceding attempts having failed.
Misspelling: IIL-60; Note=Occasionally.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2858093).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=17088437; Cosmic-CLP=905938; DepMap=ACH-000002).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; Cosmic-CLP=905938; DepMap=ACH-000002).
HLA typing Source: PubMed=26589293
Class I

Source: DSMZCellDive=ACC-3
Class I
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.42
East Asian, North0.4
East Asian, South0
South Asian0
European, North71.71
European, South26.32
Disease Adult acute myeloid leukemia (NCIt: C9154)
Acute myeloid leukemia (ORDO: Orphanet_519)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_2892 (Eos-HL-60)CVCL_8439 (HIMeg-1)CVCL_UM46 (HL-60 248)
CVCL_VK43 (HL-60 blast)CVCL_2493 (HL-60 clone 15)CVCL_B6DR (HL-60 clone F8)
CVCL_B6DS (HL-60 clone H6)CVCL_WZ17 (HL-60 DeltaF508-CF)CVCL_UM47 (HL-60 SCX3)
CVCL_UM48 (HL-60 SN3)CVCL_C8HP (HL-60(DM))CVCL_A794 (HL-60(TB))
CVCL_C8HN (HL-60-79B)CVCL_A4BY (HL-60-Luc2)CVCL_4635 (HL-60-R2)
CVCL_WW75 (HL-60-Y3)CVCL_YP33 (HL-60/5FU)CVCL_0304 (HL-60/ADR)
CVCL_IP18 (HL-60/AMSA)CVCL_WR44 (HL-60/AR)CVCL_4V19 (HL-60/ara-C [Japan 2011])
CVCL_Z938 (HL-60/ara-C [USA 1984])CVCL_C3M3 (HL-60/CDDP)CVCL_4458 (HL-60/DNR)
CVCL_D1L6 (HL-60/LRARa403SN D.2)CVCL_D1L7 (HL-60/LRARa403SN D.5)CVCL_3332 (HL-60/MX1)
CVCL_II78 (HL-60/R3)CVCL_XE38 (HL-60/RS)CVCL_II77 (HL-60/S4)
CVCL_0305 (HL-60/VCR)CVCL_4967 (HL-60/Vinc)CVCL_YT56 (HL-60R)
CVCL_RS49 (HL-60rARA-C2mug/ML)CVCL_4V55 (HL/CAFdA20)CVCL_AR88 (HL60 Ast.1)
CVCL_AR85 (HL60 Ast.25)CVCL_2495 (HL60 Ast.3)CVCL_2496 (HL60 Ast.4)
CVCL_2497 (HL60 M2)CVCL_2498 (HL60 M4)CVCL_AR89 (HL60 Sp1)
CVCL_2944 (HL60(S))CVCL_C1LK (HL60-CDR)CVCL_WI27 (HL60/AR)
CVCL_A0ST (HL60/MRI)CVCL_2945 (HL60RG)CVCL_8710 (HP100-1)
CVCL_8711 (HP50-2)CVCL_YN03 (NDi001-A)CVCL_D567 (OM10.1)
CVCL_0478 (P39)CVCL_2162 (PLB-985)CVCL_8907 (RED-3)
CVCL_J128 (VXG3)CVCL_J129 (XQH)CVCL_8931 (YJ)
Sex of cell Female
Age at sampling 36Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0003023/4977; ATCC=CCL-240; CCRID; CLS=300209; COG; Cosmic-CLP=905938; DSMZ=ACC-3; ECACC=98070106; JCRB=IFO50022; JCRB=JCRB0085; KCLB=10240; PubMed=11416159; PubMed=25877200; RCB=RCB0041; TKG=TKG 0345

D8S117912 (DSMZ=ACC-3)
12,13 (ATCC=CCL-240; CCRID; PubMed=11416159; PubMed=25877200)
13 (CLS=300209)
D18S5114 (CLS=300209)
14,15 (ATCC=CCL-240; CCRID; DSMZ=ACC-3; PubMed=11416159; PubMed=25877200)
D21S1129,30 (ATCC=CCL-240; CCRID; COG; DSMZ=ACC-3; PubMed=25877200)
30 (CLS=300209; PubMed=11416159)
Penta D10,11 (DSMZ=ACC-3)
10,12 (ATCC=CCL-240; CLS=300209; PubMed=25877200)
Penta E13 (CLS=300209)
13,14 (ATCC=CCL-240; DSMZ=ACC-3; PubMed=25877200)
TH017,8 (AddexBio=C0003023/4977; ATCC=CCL-240; CCRID; CLS=300209; COG; Cosmic-CLP=905938; DSMZ=ACC-3; JCRB=JCRB0085; KCLB=10240; PubMed=11416159; PubMed=25877200; RCB=RCB0041; TKG=TKG 0345)
8 (ECACC=98070106; JCRB=IFO50022)

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/HL60

PubMed=271272; DOI=10.1038/270347a0
Collins S.J., Gallo R.C., Gallagher R.E.
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.
Nature 270:347-349(1977)

PubMed=288488; DOI=10.1182/blood.V54.3.713.713
Gallagher R.E., Collins S.J., Trujillo J.M., McCredie K.B., Ahearn M.J., Tsai S., Metzgar R.S., Aulakh G., Ting R., Ruscetti F.W., Gallo R.C.
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia.
Blood 54:713-733(1979)

PubMed=6996765; DOI=10.1182/blood.V56.3.344.344
Koeffler H.P., Golde D.W.
Human myeloid leukemia cell lines: a review.
Blood 56:344-350(1980)

PubMed=6255959; DOI=10.1016/0014-4827(81)90422-5
Olsson I., Olofsson T.
Induction of differentiation in a human promyelocytic leukemic cell line (HL-60). Production of granule proteins.
Exp. Cell Res. 131:225-230(1981)

PubMed=6945469; DOI=10.1016/0145-2126(81)90018-7
Major P.P., Griffin J.D., Minden M.D., Kufe D.W.
A blast subclone of the HL-60 human promyelocytic cell line.
Leuk. Res. 5:429-430(1981)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6091813; DOI=10.1182/blood.V64.5.1059.1059
Palumbo A., Minowada J., Erikson J., Croce C.M., Rovera G.
Lineage infidelity of a human myelogenous leukemia cell line.
Blood 64:1059-1063(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2858093; DOI=10.1073/pnas.82.3.790
Wolf D., Rotter V.
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.
Proc. Natl. Acad. Sci. U.S.A. 82:790-794(1985)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C.
Leuk. Res. 9:549-559(1985)

Bhalla K.N., Hindenburg A.A., Taub R.N., Grant S.
Isolation and characterization of an anthracycline-resistant human leukemic cell line.
Cancer Res. 45:3657-3662(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3311197; DOI=10.1182/blood.V70.5.1233.1233
Collins S.J.
The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.
Blood 70:1233-1244(1987)

Morikawa S., Harada T., Katoh T.
Heterogeneity of cellular origins in human malignant lymphoma cell line derived from histo-monocytic lineage cells.
(In) Cellular, molecular, genetic approaches to immunodiagnosis and immunotherapy. 8th International conference on labeled antibodies, Tokyo, November 1985; Kano K., Mori S., Sugisaki T., Torisu M. (eds.); pp.373-380; Karger; Basel (1988)

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=3422031; DOI=10.1182/blood.V71.1.242.242
Dalton W.T. Jr., Ahearn M.J., McCredie K.B., Freireich E.J., Stass S.A., Trujillo J.M.
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.
Blood 71:242-247(1988)

Hindenburg A.A., Gervasoni J.E. Jr., Krishna S., Stewart V.J., Rosado M., Lutzky J., Bhalla K.N., Baker M.A., Taub R.N.
Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.
Cancer Res. 49:4607-4614(1989)

PubMed=1970118; DOI=10.1128/mcb.10.5.2154-2163.1990
Collins S.J., Robertson K.A., Mueller L.
Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha).
Mol. Cell. Biol. 10:2154-2163(1990)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=1368402; DOI=10.1007/BF02540028
Schumpp-Vonach B., Schlaeger E.-J.
Growth study of lactate and ammonia double-resistant clones of HL-60 cells.
Cytotechnology 8:39-44(1992)

PubMed=1574572; DOI=10.2307/3578273
Dunphy E.J., Beckett M.A., Thompson L.H., Weichselbaum R.R.
Expression of the polymorphic human DNA repair gene XRCC1 does not correlate with radiosensitivity in the cells of human head and neck tumor cell lines.
Radiat. Res. 130:166-170(1992)

PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J., Olive P.L.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)

Kajigaya Y., Sasaki H., Ikuta K., Matsuyama S., Hirabayashi Y., Inoue T.
Serum-free culture for leukemia cells.
Hum. Cell 6:49-56(1993)

Zhou M.-X., Gu L.-B., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

Banerjee D., Lenz H.-J., Schnieders B., Manno D.J., Ju J.-F., Spears C.P., Hochhauser D., Danenberg K.D., Danenberg P.V., Bertino J.R.
Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress.
Cell Growth Differ. 6:1405-1413(1995)

Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=9434637; DOI=10.1006/excr.1997.3813
Piepmeier E.H., Kalns J.E., McIntyre K.M., Lewis M.L.
Prolonged weightlessness affects promyelocytic multidrug resistance.
Exp. Cell Res. 237:410-418(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9557624; DOI=10.1038/sj.leu.2400976
Mattii L., Barale R., Petrini M.
Use of the comet test in the evaluation of multidrug resistance of human cell lines.
Leukemia 12:627-632(1998)

Ju J.-F., Banerjee D., Lenz H.-J., Danenberg K.D., Schmittgen T.C., Spears C.P., Schonthal A.H., Manno D.J., Hochhauser D., Bertino J.R., Danenberg P.V.
Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
Clin. Cancer Res. 4:1315-1322(1998)

PubMed=9737686; DOI=10.1038/sj.leu.2401112
Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383-1391(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=16120335; DOI=10.1016/S1567-7249(03)00010-2
Levin B.C., Holland K.A., Hancock D.K., Coble M., Parsons T.J., Kienker L.J., Williams D.W., Jones M., Richie K.L.
Comparison of the complete mtDNA genome sequences of human cell lines-- HL-60 and GM10742A -- from individuals with pro-myelocytic leukemia and Leber hereditary optic neuropathy, respectively, and the inclusion of HL-60 in the NIST human mitochondrial DNA standard reference material -- SRM 2392-I.
Mitochondrion 2:387-400(2003)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22032829; DOI=10.1016/j.mrfmmm.2011.10.005
Luan Y., Kogi M., Rajaguru P., Ren J., Yamaguchi T., Suzuki K., Suzuki T.
Microarray analysis of responsible genes in increased growth rate in the subline of HL60 (HL60RG) cells.
Mutat. Res. 731:20-26(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22944676; DOI=10.1515/hsz-2012-0195
Reinke S.O., Bayer M., Berger M., Hinderlich S., Blanchard V.
The analysis of N-glycans of cell membrane proteins from human hematopoietic cell lines reveals distinctions in their pattern.
Biol. Chem. 393:731-747(2012)

PubMed=23955599; DOI=10.1038/ng.2731
Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S., Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D., Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K., Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S., Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H., Haferlach T., Shirahige K., Miyano S., Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat. Genet. 45:1232-1237(2013)

PubMed=24368162; DOI=10.1016/j.exphem.2013.12.004
Sripayap P., Nagai T., Uesawa M., Kobayashi H., Tsukahara T., Ohmine K., Muroi K., Ozawa K.
Mechanisms of resistance to azacitidine in human leukemia cell lines.
Exp. Hematol. 42:294-306(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28109323; DOI=10.1186/s13045-017-0396-0
Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A., Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M., Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
J. Hematol. Oncol. 10:26.1-26.5(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29491412; DOI=10.1038/s41388-018-0150-2
Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D., Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N., Gerstberger T., Zuber J., Savarese F., Kraut N.
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene 37:2687-2701(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30670178; DOI=10.1016/j.jcf.2018.06.007
Jennings S., Ng H.P., Wang G.-S.
Establishment of a DeltaF508-CF promyelocytic cell line for cystic fibrosis research and drug screening.
J. Cyst. Fibros. 18:44-53(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=33389257; DOI=10.1007/s10096-020-04106-0
Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.
Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections (Providers) Abcam; ab282204 - Discontinued
AddexBio; C0003023/4977
BCRC; 60027
BCRJ; 0104
CLS; 300209
ECACC; 98070106
ICLC; HTL95010
JCRB; IFO50022
JCRB; NIHS0086 - Discontinued
KCB; KCB 2014051YJ
KCLB; 10240
NCBI_Iran; C217
RCB; RCB0041
RCB; RCB3683
TKG; TKG 0345
Ubigene; YC-C058
Cell line databases/resources CLO; CLO_0003775
CLO; CLO_0050972
MCCL; MCC:0000195
CLDB; cl1682
CLDB; cl1684
CLDB; cl1685
CLDB; cl1686
CLDB; cl1687
CLDB; cl1688
CLDB; cl1689
CLDB; cl1690
CLDB; cl1691
CLDB; cl1693
cancercelllines; CVCL_0002
CCRID; 1101HUM-PUMC000037
Cell_Model_Passport; SIDM00829
Cosmic-CLP; 905938
DepMap; ACH-000002
DSMZCellDive; ACC-3
IGRhCellID; HL60
Lonza; 64
TOKU-E; 1488
Anatomy/cell type resources BTO; BTO:0000738
Biological sample resources BioSample; SAMN01821559
BioSample; SAMN01821682
BioSample; SAMN03472768
BioSample; SAMN03473174
BioSample; SAMN10988245
CRISP screens repositories BioGRID_ORCS_Cell_line; 42
Chemistry resources ChEMBL-Cells; CHEMBL3307654
ChEMBL-Targets; CHEMBL383
GDSC; 905938
PharmacoDB; HL60_546_2019
PubChem_Cell_line; CVCL_0002
Encyclopedic resources Wikidata; Q5630035
Experimental variables resources EFO; EFO_0002793
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM50194
GEO; GSM50258
GEO; GSM213809
GEO; GSM236782
GEO; GSM236818
GEO; GSM472908
GEO; GSM472942
GEO; GSM482507
GEO; GSM545496
GEO; GSM545497
GEO; GSM743458
GEO; GSM749688
GEO; GSM749775
GEO; GSM750812
GEO; GSM799346
GEO; GSM799409
GEO; GSM838428
GEO; GSM838429
GEO; GSM838430
GEO; GSM838431
GEO; GSM887083
GEO; GSM888153
GEO; GSM945222
GEO; GSM945255
GEO; GSM1153417
GEO; GSM1181331
GEO; GSM1181348
GEO; GSM1374535
GEO; GSM1374536
GEO; GSM1446736
GEO; GSM1669883
GEO; GSM2716740
GEO; GSM2716741
GEO; GSM2716742
GEO; GSM2716743
Medical resources MeSH; D018922
Polymorphism and mutation databases Cosmic; 716179
Cosmic; 716190
Cosmic; 724817
Cosmic; 787433
Cosmic; 798224
Cosmic; 798665
Cosmic; 808506
Cosmic; 821043
Cosmic; 850380
Cosmic; 851996
Cosmic; 875866
Cosmic; 905938
Cosmic; 919116
Cosmic; 922161
Cosmic; 922683
Cosmic; 924049
Cosmic; 932769
Cosmic; 947366
Cosmic; 949099
Cosmic; 975252
Cosmic; 981578
Cosmic; 991557
Cosmic; 994170
Cosmic; 999724
Cosmic; 1012068
Cosmic; 1019836
Cosmic; 1037661
Cosmic; 1070693
Cosmic; 1078724
Cosmic; 1089519
Cosmic; 1092602
Cosmic; 1107177
Cosmic; 1127250
Cosmic; 1130234
Cosmic; 1168468
Cosmic; 1176580
Cosmic; 1181599
Cosmic; 1191695
Cosmic; 1192826
Cosmic; 1226863
Cosmic; 1281315
Cosmic; 1305337
Cosmic; 1308224
Cosmic; 1319549
Cosmic; 1451845
Cosmic; 1465966
Cosmic; 1523825
Cosmic; 1524830
Cosmic; 1582390
Cosmic; 1601062
Cosmic; 1604861
Cosmic; 1998444
Cosmic; 2036678
Cosmic; 2089652
Cosmic; 2131539
Cosmic; 2301565
Cosmic; 2306208
Cosmic; 2651387
IARC_TP53; 21372
IARC_TP53; 21731
LiGeA; CCLE_789
Progenetix; CVCL_0002
Proteomic databases PRIDE; PRD000345
PRIDE; PXD000589
PRIDE; PXD006421
PRIDE; PXD030304
PRIDE; PXD032942
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number49